Back to Faculty

Patricia Kane, PhD


Patricia Kane, PhD

Dr. Kane's dedication and success in working with patients with fragile brain architecture has brought her widespread recognition in the field of biometabolic intervention by blending lipid bench science, medical lipid research with clinical medicine by which she coined the term Membrane Medicine. She is an accomplished international lecturer, biomedical researcher and author of medical book chapters, books and medical papers. Dr. Kane serves as Director of the NeuroLipid Research Foundation, a 501c3 nonprofit organization in Millville, New Jersey. Her expertise in boldly addressing neurological disorders and lipid disturbance with targeted nutritional intervention for neurological disorders has led to direct biometabolic application utilized by physicians and researchers worldwide. Dr. Kane's clinical experience, working with physicians, spans 39 years. Dr. Kane has pioneered targeted metabolic application of the red cell fatty acid analysis from university based analysis over the past 21 years. Using basic blood chemistry / CBC she has been able to integrate biomedical interventions for both pediatric and adult populations with acute as well as chronic conditions. She expanded her biomedical model by adding on a specialized epigenetic analysis ‘a portal into the cell’ whereby images of the membrane surface, phospholipids and mitochondria of each patient along with their DNA adducts were utilized to approach the patient’s epigenetic aberrations. After application of oral and intravenous bioactive lipid intervention, both improvement in the patients’ clinical status and normalization of the phospholipids per red cell analysis and membrane imaging. Dr. Kane’s work has expedited the incorporation of current research and evidence based medicine directly into clinical practice to yield resolution of some of the complex medical disorders of our time. Dr. Kane has successfully approached refractory disorders with Membrane Stabilizing therapy: Alzheimer’s, Autism, Pervasive Developmental Delay, Seizure Disorders, Traumatic Brain Injury, Chronic Traumatic Encephalopathy, Inborn Errors in Metabolism/genetic disorders, Epigenetic insult, Neurotoxicity (Toxic & Viral Encephalopathy, Neurotoxic Fungal exposure), Post Stroke, MS, ALS, neuroinflammatory, autoimmune disorders, chronic infections including Neurolyme, psychiatric disorders, and Parkinson’s Disease. Dr. Kane developed an intravenous protocol, the Membrane Stabilizing PK Protocol using IV phospholipid therapy and oral bioactive lipid supplementation that has resulted in positive patient outcomes being utilized by thousands of physicians in the USA and internationally.

Dr. Kane has pioneered targeted metabolic application of fatty acid analysis with lipid testing from Kennedy Krieger Institute's Peroxisomal Diseases Laboratory. Using basic blood chemistry (Chem 28) and a complete blood count (CBC) Dr. Kane has been able to integrate biomedical interventions for pediatric and adult populations with acute as well as chronic conditions and states of neurotoxicity. Her work has expedited the incorporation of current research, evidence based medicine, directly into clinical practice to yield resolution of some of the complex medical disorders of our time.

Dr. Kane has had a long-standing interest in the challenging area of the treatment of severe neurological disorders such as ALS, Parkinson's Disease, Multiple Sclerosis, Alzheimer's, Autism, pervasive developmental delay, seizure disorders, Post Stroke, traumatic brain injury, metabolic and genetic abnormalities. She has developed an intravenous protocol called the PK Protocol for these devastating health disorders using IV Lipid therapy and oral fatty acid supplementation that has yielded marked positive responses. Her dedication and success in working with patients with fragile brain architecture has brought her widespread recognition in the field of biomedical intervention.